When February 21-23, 2020
Where JW Marriott Miami Turnberry Miami, Florida

Register Today
www.ResearchToPractice.com/Meetings/GMO2020

The Second Annual Miami General Medical Oncology Symposium

The meeting will feature a multimodal format focused on the solid and hematologic cancers that make up the majority of general medical oncology practice.

In response to the phenomenal surge in new drug approvals, a major emphasis of the meeting will be the safe and appropriate integration of novel agents into current management algorithms.

A portion of every tumor-specific module will be dedicated to controversial issues across the cancer care continuum, including interdisciplinary concerns, end-of-life planning, complementary therapies, psychosocial support and other relevant topics.

Interactive polling and a proprietary live chat function will allow peer-to-peer comparison and commentary throughout the event.

The program will include extensive opportunities for audience members to register their opinions and perspectives to help better define the current realities of general medical oncology practice and shape future educational resources.

The meeting will be the safe and appropriate integration of novel agents into current management algorithms.

A portion of every tumor-specific module will be dedicated to controversial issues across the cancer care continuum, including interdisciplinary concerns, end-of-life planning, complementary therapies, psychosocial support and other relevant topics.

Interactive polling and a proprietary live chat function will allow peer-to-peer comparison and commentary throughout the event.

The program will include extensive opportunities for audience members to register their opinions and perspectives to help better define the current realities of general medical oncology practice and shape future educational resources.

Key Features of the Symposium
- The meeting will feature a multimodal format focused on the solid and hematologic cancers that make up the majority of general medical oncology practice.
- In response to the phenomenal surge in new drug approvals, a major emphasis of the meeting will be the safe and appropriate integration of novel agents into current management algorithms.
- A portion of every tumor-specific module will be dedicated to controversial issues across the cancer care continuum, including interdisciplinary concerns, end-of-life planning, complementary therapies, psychosocial support and other relevant topics.
- Interactive polling and a proprietary live chat function will allow peer-to-peer comparison and commentary throughout the event.
- The program will include extensive opportunities for audience members to register their opinions and perspectives to help better define the current realities of general medical oncology practice and shape future educational resources.
In early 2019 we realized a long-term goal by hosting our First Annual Miami General Medical Oncology Symposium, a weekend-long event led by 31 distinguished clinical investigators providing a wealth of expert perspectives and diverse clinical experiences. In preparing for that event we collected data from our general medical oncology audience, which informed the program’s structure and highlighted the complex clinical management issues these practitioners encounter in their daily practice.

The program was among the most effective and well-received activities we have offered, and for this reason we are pleased to announce the conference’s return to Florida in February 2020. We will again assemble an exceptional faculty panel with the goal of directly addressing the needs of this most important component of the cancer treatment continuum, general medical oncologists and their treatment teams. This stand-alone symposium will follow a fast-paced format that emphasizes practical cancer treatment continuum, general medical oncologists and their treatment teams.

In preparing for that event we collected data from our general medical oncology audience, which informed the program’s structure and highlighted the complex clinical management issues these practitioners encounter in their daily practice. To augment the conference’s interactivity, each clinician will be provided with a specially configured iPad® to use throughout the program to participate in audience polling, view all the presentation slides and anonymously submit questions to the panelists.

We hope you will make plans to join us as we continue to redefine the value of the cancer conference for the general medical oncologist.

Join Us for a Truly Unique Educational Experience

Moderator
Neil Love, MD
Research To Practice
Miami, Florida

Participate in interactive polling and Q&A throughout the meeting using a unique technology system featuring networked iPads.

Friday, February 21st
7:00 PM – 8:30 PM
Keynote Session
Chronic Lymphocytic Leukemia
Matthew S Davids, MD, MMSc
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony R Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

Kerry Rogers, MD
The Ohio State University
Columbus, Ohio

8:05 AM – 8:55 AM
Colorectal and Gastric Cancer
Johanna Bendell, MD
Sarah Cannon Research Institute
Nashville, Tennessee

John L Marshall, MD
Lombard Comprehensive Cancer Center
Georgetown University
Washington, DC

8:55 AM – 9:45 AM
Hepatocellular Carcinoma and Pancreatic Cancer
Tanios Bakslai-Saab, MD
Mayo Clinic
Phoenix, Arizona

Weis A Messersmith, MD
University of Colorado Cancer Center
Aurora, Colorado

10:00 AM – 10:50 AM
Dermatologic Cancers
Jason J Luce, MD
University of Pittsburgh Medical Center and Hillman Cancer Center
Pittsburgh, Pennsylvania

Jeffrey S Weber, MD, PhD
NYU Langone Medical Center
New York, New York

10:50 AM – 11:40 AM
Hodgkin and Non-Hodgkin Lymphomas
Jonathan W Friedberg, MD, MMSc
James P Wilmot Cancer Institute
University of Rochester Rochester, New York

Mitchell S Smith, MD, PhD
Iowa Cancer Center
Washington, DC

11:40 AM – 12:30 PM
Diffuse Large B-Cell Lymphoma/CAR T-Cell Therapy
Jeremy Abramson, MD
Massachusetts General Hospital
Boston, Massachusetts

Sonali M Smith, MD
The University of Chicago
Chicago, Illinois

1:15 PM – 2:05 PM
Acute Leukemias
Alexander Perl, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Eytan M Stein, MD
Memorial Sloan Kettering Cancer Center
New York, New York

2:05 PM – 2:55 PM
Gynecologic Cancers
Michael J Birrer, MD, PhD
University of Arkansas
Little Rock, Arkansas

Kathleen Moore, MD
Stephenson Cancer Center
University of Oklahoma
Oklahoma City, Oklahoma

3:05 PM – 3:55 PM
ER-Positive, HER2-Negative Breast Cancer
Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, Tennessee

Virginia Kaklamani, MD, DSc
The University of Texas MD Anderson Cancer Center
San Antonio, Texas

3:55 PM – 4:45 PM
HER2-Positive and Triple-Negative Breast Cancer
Charles E Sawyer Jr, MD
Houston Methodist Cancer Center
Houston, Texas

Rita Nanda, MD
The University of Chicago
Chicago, Illinois

4:45 PM – 5:35 PM
Targeted Treatment of Lung Cancer
Hossein Borghaei, DO, MS
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Stephen V Liu, MD, PhD
Georgetown University Hospital
Washington, DC

5:35 PM – 6:25 PM
Multiple Myeloma
Eytan M Stein, MD
Memorial Sloan Kettering Cancer Center
New York, New York

10:30 AM – 11:20 AM
Immune Checkpoint Inhibitors in Lung Cancer

Sunday, February 23rd
7:45 AM – 8:35 AM
Prostate Cancer
Robert Dreicer, MD, MS
University of Virginia School of Medicine
Charlottesville, Virginia

Matthew S, MD, PhD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

8:35 AM – 9:25 AM
Renal Cell Carcinoma and Bladder Cancer

Faculty and Schedule

Joel Love, MD
Research To Practice
Miami, Florida

#oncology #education #symposium #cancerconference #research